Teva Reports Third Quarter 2020 Financial Results

Go back to Teva Reports Third Quarter 2020 Financial Results

Teva Pharma (TEVA) Reports In-Line Q3 EPS, Offer FY Guidance

November 5, 2020 7:15 AM EST

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $0.58, in-line with the analyst estimate of $0.58. Revenue for the quarter came in at $4 billion versus the consensus estimate of $4.07 billion.

GUIDANCE:

Teva Pharma sees FY2020 EPS of $2.40-$2.55, versus the consensus of... More